SCYX Share Price Performance
US$0.89
-0.01 (-1.41%)
Price US$0.89
Share Pricen/a
SCYNEXIS, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 30 Fair Values set on narratives written by author
SCYX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
SCYNEXIS, Inc. Key Details
About SCYX
- Founded
- 1999
- Employees
- 18
- CEO
- WebsiteView website
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
